# Ousia Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ousia-pharma-aps

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.ousiapharma.com/
- Latest round: Seed (May 6, 2025)
- Investors on record: 1

## About

Ousia Pharma ApS is a biotechnology firm focusing on developing innovative peptide-drug conjugates aimed at treating cardiometabolic diseases, employing unique targeting methodologies to improve patient outcomes.Founded in 2022 and located in Copenhagen, Denmark, Ousia Pharma specializes in developing advanced therapies for cardiometabolic conditions. The company has completed 2 deals to date, with their most recent deal taking place on May 6, 2025. The firm was founded by a team of experts in the biomedical field, although specific details about the founders' prior ventures are not publicly available.Ousia Pharma specializes in the development of novel peptide-drug conjugates aimed at treating cardiometabolic diseases. Their core product offerings utilize a targeting approach that delivers modulators of synaptic plasticity specifically to appetite control regions of the brain. This method addresses key metabolic disorders by enhancing the regulation of appetite and energy balance. Ousia Pharma's primary clientele includes healthcare providers and research institutions focused on metabolic health, with end users being patients suffering from various cardiometabolic conditions. Their products are positioned for markets in Europe and North America, catering to the demand for advanced therapeutic solutions in metabolic disease management.Ousia Pharma's revenue model is based on strategic partnerships and collaborations within the biomedical sector. The firm engages in B2B transactions, working directly with healthcare organizations, research entities, and pharmaceutical companies interested in innovative therapies for metabolic diseases. Revenue is generated through licensing agreements, research collaborations, and potentially through the sale of their peptide-drug conjugates once they reach market readiness. Initial funding may also come from grants and investments aimed at financing clinical trials and product advancements, with specific pricing plans for their products not disclosed.In May 2025, Ousia Pharma ApS raised an undisclosed amount of Seed funding led by Omega Funds. The company will utilize this funding to support its clinical trials and the development process of its product. Ousia Pharma plans to design and launch new products targeting cardiometabolic conditions, with specific release dates to be announced. Additionally, they are looking to expand into new markets, particularly in Europe and North America, by 2026.

## Funding rounds

- Seed, May 6, 2025 — Omega Funds

## Investors

- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Seed